Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype-Reference-Cited by-同舟云学术

Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype

Published:2016-09-06 Issue:10 Volume:126 Page:3868-3878
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Brendel Christian,Guda Swaroopa,Renella Raffaele,Bauer Daniel E.,Canver Matthew C.,Kim Young-Jo,Heeney Matthew M.,Klatt Denise,Fogel Jonathan,Milsom Michael D.,Orkin Stuart H.,Gregory Richard I.,Williams David A.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference45 articles.

1. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia

2. Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A

3. Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6

4. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A

5. Developmental and species-divergent globin switching are driven by BCL11A

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapeutic management based on phytoconstituents for sickle cell anemia focusing on molecular mechanisms: Current trends and future perspectives;Phytomedicine;2024-10

2. Role of gene therapy in sickle cell disease;Disease-a-Month;2024-07

3. A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease;Molecular Therapy - Methods & Clinical Development;2024-06

4. International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced;Cytotherapy;2024-06

5. Interplay between α‐thalassemia and β‐hemoglobinopathies: Translating genotype–phenotype relationships into therapies;HemaSphere;2024-05